Corporate News
Incorporation of a wholly owned subsidiary
Its portfolio company, Diurnal Group plc has announced headline data from the Chronocort® pivotal Phase III clinical trial in Europe for adults with congenital adrenal hyperplasia (CAH). The primary objective of the trial was not met.
10/10/2018 09:08:01
Note from Publisher
Stock Selections
Corporate News